收盘价:Aug 12, 16:00:00 GMT-4
盘后:Aug 12, 19:47:35 GMT-4
No Data Yet
Regeneron Pharmaceuticals faces a securities class action lawsuit after its failed Phase 3 melanoma trial erased $11 billion in market value.
Regeneron Pharmaceuticals faces a securities class action after its Phase 3 melanoma trial failed, wiping out $11 billion in market value.
Regeneron Pharmaceuticals reported Q2 2026 earnings that beat Wall Street expectations, driven by strong Dupixent sales growth.
Regeneron Pharmaceuticals Inc 的市盈率是 18.1584
Dr. Leonard Schleifer 是 Regeneron Pharmaceuticals Inc 的 Co-Chairman of the Board,自 1988 加入公司。
REGN 的当前价格为 $796.23,在上个交易日 下降 了 0%。
Regeneron Pharmaceuticals Inc 属于 Biotechnology 行业,该板块是 Health Care
Regeneron Pharmaceuticals Inc 的当前市值是 $83.4B
据华尔街分析师称,共有 33 位分析师对 Regeneron Pharmaceuticals Inc 进行了分析师评级,包括 10 位强烈买入,17 位买入,7 位持有,1 位卖出,以及 10 位强烈卖出